Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106973 · ClinicalTrials.gov registry record
Mesothelioma Early Detection by VOCs
A clinical trial, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- 12
- Enrollment target
NCT04106973 is a clinical trial that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 12 participants.
The verdict
NCT04106973 was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
This is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma. The second phase (phase 2), is a double blinded case-matched controlled study to determine the predictive capability, sensitivity, and specificity of these biomarkers in detecting early stage pleural mesothelioma. Biomarkers in the form of volatile organic compounds (VOC) in exhaled breath samples from subjects with either pleural mesothelioma or pleural plaques, will be evaluated. A biomarker present in serum will also be concurrently evaluated in the same cohort. The soluble serum biomarker mesothelin related peptides (SMRP), which has been posited as a biomarker for mesothelioma, will be analyzed for its relationship to the breath VOC profile.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-06-05 |
| Est. Completion | 2022-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04106973
The ClinicalTrials.gov registry entry for NCT04106973 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04106973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04106973 about?
NCT04106973 is a clinical study titled "Mesothelioma Early Detection by VOCs". This is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma. The second phase (phase 2), is a double blinded case-matched controlled study to determine the predictive capability, sensitivity, and specificity of ...
What is the current status of trial NCT04106973?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2019-06-05. Estimated completion is 2022-01-01.
Who is sponsoring clinical trial NCT04106973?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.